Acrux(OTC) ARUXF

Acrux Limited specializes in the global development and commercialization of generic and topical pharmaceutical products. The company focuses on testosterone therapies and estradiol sprays, catering to both men and women with specific health needs.

Products and Services

• Diverse testosterone therapies in various forms
• Estradiol sprays for menopausal women
• Topical pharmaceutical products for global markets

Growth Outlook

• Recent quarterly revenue reached AUD 2.9 million, showing potential for growth
• Gross profit margin improved to 92.6% in the latest quarter
• Expansion into international markets continues to drive product demand

Financial Highlights

• Trailing twelve months revenue of AUD 10.5 million
• Net income for the latest quarter was AUD -767,921
• Cash and cash equivalents totaled AUD 1.7 million as of June 30, 2026

Acrux Limited operates within the biotechnology sector, focusing on innovative solutions for hormone-related health issues. The company has established a strong presence in international markets, including Australia, Europe, and the United States. With a diverse product portfolio, Acrux aims to address the needs of patients experiencing low testosterone levels and menopausal symptoms. Recent financial performance indicates a significant revenue increase, with the latest quarterly revenue reaching AUD 2.9 million. The gross profit margin has shown improvement, reflecting effective cost management and product pricing strategies. Despite reporting a net loss in the latest quarter, the company maintains a solid cash position, which supports ongoing research and development efforts. Investors may find Acrux Limited an intriguing opportunity due to its focus on niche markets and potential for growth in the pharmaceutical sector. The company's commitment to innovation and expansion could position it favorably in the competitive landscape of biotechnology.